Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Stevanato Group (STVN)
NYSE:STVN
Holding STVN?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.19Last Year’s EPS
0.19Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 09, 2021
|% Change Since: 17.91%
|Next Earnings Date:Aug 19, 2021
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with solid growth in high-value solutions and progress in capacity expansion, but faced significant challenges such as lowered annual guidance, engineering segment difficulties, and ongoing vial destocking impacts.Company Guidance
During Stevanato Group's third-quarter 2024 earnings call, the company adjusted its full-year guidance, lowering expectations for adjusted EBITDA to a range of EUR 257 million to EUR 263 million and adjusted diluted EPS to EUR 0.47 to EUR 0.49, while maintaining revenue guidance between EUR 1.090 billion and EUR 1.110 billion. This adjustment was primarily due to higher costs in the Engineering segment related to an optimization plan and increased validation activities in the U.S. Revenue for the quarter grew by 2% to EUR 277.9 million, with a significant 17% increase in high-value solutions, now representing 36% of total revenue. Gross profit margin declined to 26.8% due to vial destocking and startup inefficiencies at new facilities in Fishers and Latina. Despite these challenges, the company anticipates a strong fourth quarter for high-value solutions, expecting them to constitute 37% to 39% of total revenue for the full year.High-Value Solutions Growth
Revenue from high-value solutions grew 17% driven by high-value syringes and represented approximately 36% of total revenue in the quarter versus 32% last year.
Capacity Expansion Progress
Fishers achieved a major milestone with a successful launch of commercial production, generating first commercial revenue. Latina became profitable at the gross profit level in Q3 2024.
Alliance for RTU Launch
The launch of the Alliance for RTU with other industry players has generated significant interest, aiming to educate the pharmaceutical industry on ready-to-use vial and cartridge solutions.
Strategic Supply Agreement for Needle-Free Spray
Stevanato Group won a strategic supply agreement to support the first needle-free epinephrine nasal spray, producing premium micro vials for the neffy device.
---
STVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
STVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $19.38 | $22.50 | +16.10% |
| Aug 06, 2024 | $18.79 | $19.87 | +5.75% |
| May 09, 2024 | $26.83 | $21.04 | -21.58% |
| Mar 07, 2024 | $33.00 | $30.29 | -8.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Stevanato Group (STVN) report earnings?
Stevanato Group (STVN) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Stevanato Group (STVN) earnings time?
Stevanato Group (STVN) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STVN EPS forecast?
STVN EPS forecast for the fiscal quarter 2024 (Q4) is 0.19.
---